Peripheral Artery Disease

Philips announced that a mechanical thrombectomy system to remove blood clots from vessels within the peripheral arterial and venous systems has received 510(k) clearance from the FDA and is now available in the U.S.

Among patients with peripheral artery disease who underwent revascularization, those with concomitant clinical evidence of CAD received greater absolute benefit of reduced risk for MACE from taking low-dose rivaroxaban than those with PAD without CAD.

Researchers have found that women with peripheral artery disease were more likely to present with depressive symptoms than men, worsening their health status.

Women with peripheral artery disease were more likely to have depressive symptoms compared with men, researchers found.

Hispanic and Latino patients with peripheral artery disease underuse guideline-recommended CV medications such as antiplatelet and lipid-lowering therapies, researchers found.

Patients with peripheral artery disease were less likely to be treated with statin therapy compared with those with cerebrovascular disease or CHD despite having a high risk for atherosclerotic CVD events, researchers found.

In an analysis of the EUCLID trial, factors associated with major amputation in peripheral artery disease included diabetes, prior amputation, critical limb ischemia and an ankle-brachial index of less than 0.8.

In a retrospective, adjusted analysis of Medicare Advantage beneficiaries who underwent peripheral vascular interventions, there was no evidence of an elevated mortality risk due to paclitaxel-coated devices.

Among patients with new or worsening peripheral artery disease, chronic stress was independently associated with elevated risk for all-cause mortality in the subsequent 4 years, researchers reported.

Healio and Cardiology Today have compiled a list of the top read news in CV and dietary health.